Lees Pharmaceutical Holdings Stock Net Income
| LPCUFDelisted Stock | USD 0.0001 0.00 0.00% |
Lees Pharmaceutical Holdings fundamentals help investors to digest information that contributes to Lees Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Lees Pink Sheet. The fundamental analysis module provides a way to measure Lees Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lees Pharmaceutical pink sheet.
Lees |
Lees Pharmaceutical Holdings Company Net Income Analysis
Lees Pharmaceutical's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Lees Pharmaceutical Net Income | 1.99 B |
Most of Lees Pharmaceutical's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lees Pharmaceutical Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Lees Pharmaceutical Holdings reported net income of 1.99 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is significantly lower than that of the firm.
Lees Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lees Pharmaceutical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Lees Pharmaceutical could also be used in its relative valuation, which is a method of valuing Lees Pharmaceutical by comparing valuation metrics of similar companies.Lees Pharmaceutical is currently under evaluation in net income category among its peers.
Lees Fundamentals
| Return On Equity | -0.0531 | |||
| Return On Asset | 0.0591 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | (1.58) % | |||
| Current Valuation | 123.64 M | |||
| Shares Outstanding | 588.84 M | |||
| Shares Owned By Insiders | 63.62 % | |||
| Shares Owned By Institutions | 6.36 % | |||
| Price To Book | 0.0002 X | |||
| Price To Sales | 0.10 X | |||
| Revenue | 1.27 B | |||
| Gross Profit | 806.28 M | |||
| EBITDA | 1.98 B | |||
| Net Income | 1.99 B | |||
| Cash And Equivalents | 368.05 M | |||
| Cash Per Share | 0.62 X | |||
| Total Debt | 84.09 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 1.04 X | |||
| Book Value Per Share | 3.64 X | |||
| Cash Flow From Operations | 210.68 M | |||
| Number Of Employees | 1.32 K | |||
| Beta | 0.91 | |||
| Market Capitalization | 275.66 B | |||
| Total Asset | 3.64 B | |||
| Annual Yield | 52.23 % | |||
| Net Asset | 3.64 B | |||
| Last Dividend Paid | 0.041 |
About Lees Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lees Pharmaceutical Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lees Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lees Pharmaceutical Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Lees Pink Sheet
If you are still planning to invest in Lees Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lees Pharmaceutical's history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |